CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro

International Journal of Molecular Medicine

Volumn 35, Issue 2, 2015, Pages 340-348

  Zhu, Zhuangyan ^a   Mu, Yaqin ^a   Qi, Caixia ^a   Wang, Jian ^a   Xi, Guoping ^a   Guo, Juncheng ^a   Mi, Ruoran ^b   Zhao, Fuxi ^a  

^a SHANXI DATONG UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450 1B1; Drug resistance; Epithelial ovarian cancer; Paclitaxel; naphthoflavone

Indexed keywords

CYTOCHROME P450 1B1; PACLITAXEL; ANTINEOPLASTIC AGENT; CYP1B1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVARY CARCINOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1B1; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 84919625716     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.2041     Document Type: Article

References (34)

1. American Cancer Society. Ovarian cancer. www.cancer.org/acs/groups/cid/documents/webcontent/003130-pdf.pdf. Accessed January 2, 2014.
2. Canevari S, Gariboldi M, Reid JF, Bongarzone I and Pierotti MA: Molecular predictors of response and outcome in ovarian cancer. J Gen Virol 60: 19-37, 2006.
3. Baldwin LA, Huang B, Miller RW, et al: Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120: 612-618, 2012.
4. Huang TC and Campbell TC: Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev 38: 613-617, 2012.
5. Mouratidou D, Gennatas C, Michalaki V, et al: A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Res 27: 681-685, 2007.
6. Lewis DF: 57 varieties: the human cytochromes P450. Pharmacogenomics 5: 305-318, 2004.
7. Nebert DW, Wikvall K and Miller WL: Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 368: 20120431, 2013.
8. Fujita K: Cytochrome P450 and anticancer drugs. Curr Drug Metab 7: 23-37, 2006.
9. Lynch T and Price A: The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76: 391-396, 2007.
10. Androutsopoulos VP, Spyrou I, Ploumidis A, et al: Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PloS One 8: e82487, 2013.
11. Murray GI, Melvin WT, Greenlee WF and Burke MD: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41: 297-316, 2001.
12. Murray GI, Patimalla S, Stewart KN, Miller ID and Heys SD: Profiling the expression of cytochrome P450 in breast cancer. Histopathology 57: 202-211, 2010.
13. Piotrowska H, Kucinska M and Murias M: Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human cancer cell lines. Mol Cell Biochem 383: 95-102, 2013.
14. Shatalova EG, Klein-Szanto AJ, Devarajan K, Cukierman E and Clapper ML: Estrogen and cytochrome P450 1B1 contribute to both early- and late-stage head and neck carcinogenesis. Cancer Prev Res (Phila) 4: 107-115, 2011.
15. Urbschat A, Paulus P, von Quernheim QF, et al: Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma. Eur J Clin Invest 43: 1282-1290, 2013.
16. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J and Murray GI: Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62: 207-212, 2001.
17. Downie D, McFadyen MC, Rooney PH, et al: Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 11: 7369-7375, 2005.
18. Rochat B, Morsman JM, Murray GI, Figg WD and McLeod HL: Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296: 537-541, 2001.
19. McFadyen MC, Cruickshank ME, Miller ID, et al: Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 85: 242-246, 2001.
20. Gibson P, Gill JH, Khan PA, et al: Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther 2: 527-534, 2003.
21. McFadyen MC, Melvin WT and Murray GI: Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3: 363-371, 2004.
22. Scripture CD, Sparreboom A and Figg WD: Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6: 780-789, 2005.
23. Vaclavikova R, Soucek P, Svobodova L, et al: Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 32: 666-674, 2004.
24. Rochat B: Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44: 349-366, 2005.
25. Foland TB, Dentler WL, Suprenant KA, Gupta ML Jr and Himes RH: Paclitaxel-induced microtubule stabilization causes mitotic block and apoptotic-like cell death in a paclitaxel-sensitive strain of Saccharomyces cerevisiae. Yeast 22: 971-978, 2005.
26. Sun X, Li D, Yang Y, et al: Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity. J Pathol 226: 666-673, 2012.
27. Marsh S, Somlo G, Li X, et al: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7: 362-365, 2007.
28. Bournique B and Lemarie A: Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos 30: 1149-1152, 2002.
29. Singh PB, Ragavan N, Ashton KM, Basu P, Nadeem SM and Nicholson CM: Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. Asian J Androl 12: 203-214, 2010.
30. Zahid M, Beseler CL, Hall JB, Levan T, Cavalieri EL and Rogan EG: Unbalanced estrogen metabolism in ovarian cancer. Int J Cancer 134: 2414-2423, 2013.
31. Piotrowska H, Myszkowski K, Ziolkowska A, et al: Resveratrol analogue 3,4,4',5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol 263: 53-60, 2012.
32. Saini S, Hirata H, Majid S and Dahiya R: Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Res 69: 7038-7045, 2009.
33. Huang Y and Fan W: IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 61: 105-113, 2002.
34. Qiu B, Sun X, Zhang D, Wang Y, Tao J and Ou S: TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro. Int J Mol Sci 13: 9142-9156, 2012.